Disaccharide-modified liposomes and their in vitro intracellular uptake.
Sterically stabilized liposomes (SSL) were known to be accumulated passively in cancer due to the effect of enhanced permeability and retention (EPR). However, drug delivery via SSL to cancer seemed to show an insufficient improvement of chemotherapeutic efficacy. Herein, carbohydrate-binding proteins (lectins) of cell surface, which express on the plasmic membrane of many malignant cells, can be a good model of surface-modified liposomes. In this study, we investigated the in vitro characteristics of liposomes of which the surface was modified with a disaccharide molecule, sucrose or maltose. The disaccharide-modified lipids such as sucrose-modified lipid and maltose-modified lipid, in which the disaccharide was conjugated to the one end of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol)-2000 (DSPE-PEG2000), was synthesized. The disaccharide-modified liposomes were prepared by thin film-hydration method and then doxorubicin (DOX), an anticancer drug, was loaded to the prepared liposomes by the remote loading method with ammonium ion gradient. Flow cytometry and confocal microscopy analyses showed that the disaccharide-modified liposomes enhanced the intracellular uptake of liposomes into various cancer cell lines via lectin-mediated endocytosis. The disaccharide-modified liposomes in which DOX was loaded inside of liposomes exhibited higher cytotoxicity against various cancer cells than DOX-loaded SSL did. These results suggest that disaccharide-modified liposomes may be promising cancer targeting carriers which can enhance intracellular uptake and cytotoxicity of the drug-loaded liposomes via lectin-mediated endocytosis.
Song
Chung Kil
CK
Department of Pharmaceutics, College of Pharmacy, Seoul National University, Seoul, South Korea.
Jung
Suk Hyun
SH
Kim
Dae-Duk
DD
Jeong
Kyu-Sung
KS
Shin
Byung Cheol
BC
Seong
Hasoo
H
D000586:Amination; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004187:Disaccharides / Q000138:chemical synthesis / Q000737:chemistry*; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D004705:Endocytosis / Q000187:drug effects*; D006801:Humans; D008081:Liposomes / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics*; D015394:Molecular Structure; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry
C519184:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000); D000903:Antibiotics, Antineoplastic; D004187:Disaccharides; D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; D011092:Polyethylene Glycols; D004317:Doxorubicin